GlassScriptPhysician profile
Matthew T Clary
NPI 1538345004
$119,091.10
in general payments reported to CMS, 2019-2025
36 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $2,385 · 2021: $33K · 2022: $27K · 2023: $22K · 2024: $17K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $8,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,300.00 |
| Food and Beverage | $8,655.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49,537.09 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Allergan, INC. | $38,343.54 | 2019-2022 | |
| Sight Sciences, INC. | $19,330.86 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $3,558.89 | 2019-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $1,650.90 | 2019-2025 | Cequa, Xelpros |
| Ocular Therapeutix, INC. | $731.41 | 2019-2025 | Dextenza |
| New World Medical,INC. | $674.15 | 2019-2025 | Kahook Dual Blade, Streamline, Ahmed Glaucoma Valve |
| Novartis Pharmaceuticals Corporation | $600.44 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $578.23 | 2022-2025 | Vyzulta, Miebo, Envista Mx60 Iol |
| Johnson & Johnson Surgical Vision, INC. | $529.14 | 2019-2025 | Catalys System |
| Mallinckrodt Hospital Products INC. | $465.49 | 2020-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $446.67 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $381.37 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $306.59 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $284.53 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $223.71 | 2023-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Glaukos Corporation | $208.05 | 2021-2025 | Idosetr, Idose |
| Omeros Corporation | $182.00 | 2019-2020 | |
| Biotissue Holdings INC. | $160.08 | 2019-2025 | |
| Thea Pharma INC. | $123.55 | 2023-2024 | Iyuzeh |
| Amgen INC. | $112.21 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $107.24 | 2024-2025 | Vevye, Iheezo |
| Dompe US, INC. | $100.28 | 2022-2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $92.48 | 2019-2021 | |
| Optos, INC. | $64.55 | 2020 | |
| Horizon Therapeutics Plc | $56.80 | 2021-2022 | |
| Shire North American Group INC | $52.65 | 2019 | |
| Lensar, INC. | $42.80 | 2025 | Lensar Laser System |
| Eyevance Pharmaceuticals LLC | $30.37 | 2022 | |
| Rxsight INC | $25.77 | 2024 | Rxsight Injector Handpiece, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Ivantis, INC | $23.67 | 2020 | |
| Iridex Corporation | $20.12 | 2023 | |
| Mallinckrodt Enterprises LLC | $17.50 | 2019 | |
| Maculogix, INC. | $14.22 | 2020 | |
| Apellis Pharmaceuticals, INC. | $13.75 | 2025 | Syfovre |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Clary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.